Radionuclide-based therapy represents a promising new class of antineoplastic therapy whereby biomolecules (e.g., monoclonal antibodies) are radiolabeled and target a specific tumor antigen or receptor, allowing for concentration of the drug within the tumor microenvironment [84]. This evidence concerns the gene LINC01194 and neoplasm.